FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
FDA Approves First New Schizophrenia Drug In 30 Years: Cobenfy Offers Hope With Fewer Side Effects | Details
The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side ...
C&EN2d
FDA approves Cobenfy, a first-in-class schizophrenia drug
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was ...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
FiercePharma3d
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
Bristol Myers gets FDA approval for Cobenfy to treat Schizophrenia
The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
Daily1d
USFDA approves Bristol Myers Squibb Cobenfy for Schizophrenia treatment in adults
The landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where ...
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...